Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel, +27

New England Journal of Medicine

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel, +30

New England Journal of Medicine

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, +148

The Lancet Oncology

MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment +3

Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

Caroline Charlier, Élodie Perrodeau, Alexandre Leclercq, +1767

The Lancet Infectious Diseases

Prognostic FactorsFoodborne IllnessClinical FeaturesMicrobiologyInfection Control +4

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

Patrick A. Ott, Élena Elez, Sandrine Hiret, +5

Journal of Clinical Oncology

Adverse EventsPd-l1 ExpressionMedicineImmunologyTumor Immunity +10

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez, +219

The Lancet Oncology

Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor +6

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier, +21

The Lancet Oncology

Ifct-1501 Maps2Immune Checkpoint InhibitorPleural DiseaseCancer TreatmentOncology +3

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein, +16

The Lancet Oncology

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Solange Peters, Arnaud Scherpereel, Robin Cornelissen, +17

Annals of Oncology

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Delvys Rodríguez‐Abreu, Melissa L. Johnson, Maen Hussein, +17

Journal of Clinical Oncology

Pd-l1-selected NsclcImmunologyImmunoeditingPharmacotherapyImmunotherapeutics +18